Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.
Advanced Prostate Cancer|Metastatic Prostate Cancer|Locally Advanced Prostate Cancer
DRUG: Triptorelin pamoate (embonate) salt
Percentage of participants achieving castrate levels of serum testosterone (<50 ng/dL or 1.735 nmol/L), Day 29|Percentage of participants maintaining the castrate levels, From Week 8 to Week 24
Incidence of treatment emergent adverse event (TEAEs) (including local tolerability), From baseline up to Week 24|Actual values and changes from baseline in clinical laboratory tests, Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be decided by the investigator., At Week 24|Actual values and changes from baseline in physical examination, Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be decided by the investigator., At Day 1, Week 12 and Week 24|Percentages of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Readings, Percentage of participants with clinically significant changes in ECG readings will be reported. The clinical significance will be decided by the investigator., At Week 4 and Week 24|Change from baseline in vital signs measurements, Percentage of participants with clinically significant changes in Vital Signs will be reported. The clinical significance will be decided by the investigator., At each visit up to Week 24|Percent change in prostate specific antigen (PSA) from baseline (prior to injection), Percent change in PSA is defined as the absolute value of difference between the PSA values and the baseline value divided by the baseline value, At Week 12 and Week 24|Pharmacokinetics (PK) of Triptorelin: Time to Maximum Observed Drug Concentration (Tmax), Tmax will be recorded from the PK blood samples collected., Up to 24 weeks|PK of Triptorelin: Maximum Observed Plasma (peak) Drug Concentration (Cmax), Cmax will be recorded from the PK blood samples collected., Up to 24 weeks|PK of Triptorelin: Area under the Plasma Concentration Time Curve From Zero to the Time 0 to the Visit on Day 169 (AUC0-169), AUC0-169 will be recorded from the PK blood samples collected., up to Day 169|PK of Triptorelin: Area under the Plasma Concentration Time Curve From Zero to the Time 0 to the Last Quantifiable Concentration (AUClast), AUClast will be recorded from the PK blood samples collected., Up to 24 weeks|Pharmacodynamics (PD) of Testosterone: Maximum Observed Plasma (peak) Drug Concentration (Cmax), Cmax will be recorded from the PD blood samples collected., Up to 24 weeks|PD of Testosterone: Time to Maximum Observed Drug Concentration (Tmax), Tmax will be recorded from the PD blood samples collected., Up to 24 weeks|PD of Testosterone: Time to Castration(Tcast), Tcast will be recorded from the PD blood samples collected., Up to 24 weeks|Sparse plasma concentrations of triptorelin, At pre-dose and at Week 4, 8, 12, 16, 20 and 24|Sparse serum concentrations of testosterone, At pre-dose and at Week 4, 8, 12, 16, 20 and 24
The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.